ANA Reflex to ENA, in Visit Clinic

A positive ANA (antinuclear antibody) test means your immune system makes antibodies that react with cell nuclei; it’s common in autoimmune diseases (like lupus, Sjögren’s, scleroderma) but can occur in healthy people or with infections and certain drugs. ENA (extractable nuclear antigen) testing looks for specific autoantibodies (e.g., Ro, La, Sm, RNP, Scl‑70) that help identify particular connective tissue diseases. Results require clinical correlation and further evaluation.

The ANA reflex ENA test is a blood screening for antinuclear antibodies (ANA) to detect autoimmune connective-tissue diseases. If ANA is positive or shows a significant pattern, the lab reflexively performs an ENA panel to identify specific extractable nuclear antigens (e.g., anti‑Ro/SSA, anti‑La/SSB, anti‑Sm, anti‑RNP). Results help confirm diagnosis, guide further evaluation, and monitor disease activity.

Not exactly. ENA (extractable nuclear antigens) refers to a panel of specific autoantibodies targeting particular nuclear proteins. ANA is a broad screening test for antibodies against nuclear components; ENA testing identifies defined antibodies (eg, anti‑Ro, anti‑La, anti‑Sm, anti‑RNP, Scl‑70, Jo‑1) often checked when an ANA test is positive.

A positive ANA reflex means the initial antinuclear antibody screening was reactive, so the lab automatically performs follow-up tests (for example, antibody panels, pattern assessment, or specific autoantibodies) to identify targets and guide diagnosis. It indicates immune activity but is not diagnostic by itself—many healthy people and non-autoimmune conditions can be positive. Results must be interpreted with symptoms and clinical context.

Yes — many people with systemic lupus erythematosus (SLE) have positive ENA antibodies, though results vary. Anti‑Sm is relatively specific for SLE but not highly sensitive; anti‑Ro/SSA, anti‑La/SSB and anti‑RNP can also occur. A positive ENA helps characterize disease, but a negative ENA does not rule out lupus; ANA testing and clinical evaluation remain essential.

Cancers that can be associated with a positive ANA include certain solid tumors — especially lung, breast, ovarian, hepatocellular and gastrointestinal (colorectal) cancers — as well as renal cell carcinoma. Hematologic malignancies such as lymphoma and leukemia also sometimes show ANA positivity. Positive ANA in cancer often reflects paraneoplastic autoimmune phenomena rather than a primary connective tissue disease.